Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Mucopolysaccharidosis I
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Aldurazyme
Aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I; alpha-L-iduronidase deficiency) to treat the nonneurological manifestations of the disease.
View on EMAInfluenza (Healthy Volunteers)
Type 2 Diabetes Mellitus
Diphtheria
Non Small Cell Lung Cancer
Influenza